专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080108602A1 Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication 审中-公开
标题翻译：预防抗精神病药，抗抑郁药和抗癫痫药物中的肥胖
公开(公告)号：US20080108602A1
公开(公告)日：2008-05-08
申请号：US11687954
申请日：2007-03-19
申请人： Peter Literati Nagy , Jesse Roth , Zoltan Szilvassy , Kalman Tory , Mike Brownstein , Kalman Takacs , Laszlo Vigh , Jozsef Mandi , Balazs Sumegi , Sandor Bernath , Attila Kolonics , Gabor Balogh , Janos Egri
发明人： Peter Literati Nagy , Jesse Roth , Zoltan Szilvassy , Kalman Tory , Mike Brownstein , Kalman Takacs , Laszlo Vigh , Jozsef Mandi , Balazs Sumegi , Sandor Bernath , Attila Kolonics , Gabor Balogh , Janos Egri
IPC分类号： A61K31/445 , A61K31/519 , A61K31/551 , A61P3/04
CPC分类号： A61K31/4545 , A61K31/19 , A61K31/40 , A61K31/519 , A61K31/551 , A61K31/5513 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
摘要翻译： O-（3-哌啶子基-2-羟丙基） - 烟酰胺肟或其药学上合适的酸加成盐（BGP-15）可以用于预防或减轻用抗精神病药物治疗的患者体重增加或肥胖，抗抑郁药或抗癫痫药。

2. 发明申请

US20080108673A1 Prevention and Treatment of Obesity 失效
标题翻译：预防和治疗肥胖
公开(公告)号：US20080108673A1
公开(公告)日：2008-05-08
申请号：US11687945
申请日：2007-03-19
申请人： Peter Literati Nagy , Zoltan Szilvassy , Kalman Tory , Laszlo Vigh , Kalman Takacs , Jozsef Mandl , Balazs Sumegi , Sandor Bernath , Attila Kolonics , Gabor Balogh , Janos Egri
发明人： Peter Literati Nagy , Zoltan Szilvassy , Kalman Tory , Laszlo Vigh , Kalman Takacs , Jozsef Mandl , Balazs Sumegi , Sandor Bernath , Attila Kolonics , Gabor Balogh , Janos Egri
IPC分类号： A61K31/44 , A61P3/04
CPC分类号： A61K31/4545 , Y10S514/909
摘要： O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.
摘要翻译： O-（3-哌啶子基-2-羟丙基） - 烟酰胺肟或其药学上合适的酸加成盐（BGP-15）可以用于预防或减轻体重增加或减轻体重。

3. 发明授权

US06306878B1 Pharmaceutical compositions containing hydroximic acid derivatives 失效
公开(公告)号：US06306878B1
公开(公告)日：2001-10-23
申请号：US08722499
申请日：1996-09-27
申请人： Balazs Sumegi , Peter Literati Nagy , Laszlo Vigh , Bruno Maresca
发明人： Balazs Sumegi , Peter Literati Nagy , Laszlo Vigh , Bruno Maresca
IPC分类号： A61K31445
CPC分类号： A61K31/5395 , A61K31/15 , A61K31/4545 , A61K31/455 , A61K31/539
摘要： The invention refers to pharmaceutical compositions suitable for the protection of the mitochondrial genom and/or mitochondrium from damages or for the treatment of diseases connected with such damages, said compositions comprising a hydroximic acid derivative of the formula: wherein R1 represents a hydrogen or a C1-5 alkyl group, R2 stands for a hydrogen, a C1-5 alkyl group, a C3-8 cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or R1 or R2 together with the nitrogen atom they are attached to form a 5 to 8 membered ring optionally containing one or more further nitrogen, oxygen or sulfur atom(s) and said ring can be condensed with another alicyclic or heterocyclic ring, preferably a benzene, naphthalene, quinoline, isoquinoline, pyridine or pyrazoline ring, furthermore, if desired and chemically possible, the nitrogen and/or sulfur heteroatom(s) are present in the form of an oxide or dioxide, R3 means a hydrogen, a phenyl group, a naphthyl group or a pyridyl group wherein said groups can be substituted by one or more halo atom(s) or C1-4 alkoxy group(s), Y is a hydrogen, a hydroxy group, a C1-24 alkoxy group optionally substituted by an amino group, a C2-24 polyalkenyl-oxy group containing 1 to 6 double bond(s), a C1-25 alkanoyl group, C3-9 alkenoyl group or a group of the formula R7—COO—, wherein R7 represents a C2-30 polyalkenyl group containing 1 to 6 double bond(s), X stands for a halo, an amino group, a C1-4 alkoxy group, or X forms with B an oxygen atom, or X and Y together with the carbon atoms they are attached to and the —NR—O—CH2 group being between said carbon atoms form a ring of the formula wherein Z represents an oxygen or a nitrogen, R stands for a hydrogen or R forms with B a chemical bond, A is a C1-4 alkylene group or a chemical bond or a group of the formula wherein R4 represents a hydrogen, a C1-5 alkyl group, a C3-8 cycloalkyl group or a phenyl group optionally substituted by a halo, a C1-4 alkoxy group or a C1-5 alkyl group, R5 stands for a hydrogen, a C1-4 alkyl group or a phenyl group, m has a value of 0, 1 or 2, n has a value of 0, 1 or 2, or a pharmaceutically acceptable acid addition salt thereof as the active ingredient.

4. 发明申请

US20050165019A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same 失效
公开(公告)号：US20050165019A1
公开(公告)日：2005-07-28
申请号：US11084231
申请日：2005-03-21
申请人： Peter Literati Nagy , Balazs Sumegi , Kalman Takacs
发明人： Peter Literati Nagy , Balazs Sumegi , Kalman Takacs
IPC分类号： C07D295/12 , A61K31/155 , A61K31/16 , A61K31/40 , A61K31/4245 , A61K31/4453 , A61K31/454 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/5395 , A61K31/55 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/02 , A61P9/10 , A61P9/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/14 , A61P31/18 , A61P37/02 , A61P43/00 , C07C249/06 , C07C251/40 , C07D207/325 , C07D271/06 , C07D271/07 , C07D273/02 , C07D273/04 , C07D295/13 , C07D413/06 , A61K31/4709 , C07D413/02
CPC分类号： C07D271/07 , C07C251/40 , C07D273/04 , C07D295/13 , C07D413/06
摘要： The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.

5. 发明授权

US07151175B2 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same 失效
标题翻译：丙烯羧酸偕胺肟衍生物，其制备方法和含有它们的药物组合物
公开(公告)号：US07151175B2
公开(公告)日：2006-12-19
申请号：US11084231
申请日：2005-03-21
申请人： Peter Literati Nagy , Balazs Sumegi , Kalman Takacs
发明人： Peter Literati Nagy , Balazs Sumegi , Kalman Takacs
IPC分类号： C07D403/00 , C07D413/00 , C07D217/00 , C07D215/38 , C07D271/06
CPC分类号： C07D271/07 , C07C251/40 , C07D273/04 , C07D295/13 , C07D413/06
摘要： The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.
摘要翻译：本发明还涉及新的丙烯羧酸偕胺肟衍生物，另外还涉及N-氧化物和/或几何异构体和/或光学异构体和/或其药学上合适的酸加成盐和/或其季铵衍生物。新型化合物适用于治疗与缺氧和/或能量缺乏有关的状态，或者基于PARP抑制，特别是自身免疫性或神经变性疾病和/或病毒性疾病和/或由有毒的作用。

6. 发明授权

US06887872B2 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same 失效
标题翻译：丙烯羧酸偕胺肟衍生物，其制备方法和含有它们的药物组合物
公开(公告)号：US06887872B2
公开(公告)日：2005-05-03
申请号：US10239159
申请日：2001-03-13
申请人： Peter Literati Nagy , Balazs Sumegi , Kalman Takacs
发明人： Peter Literati Nagy , Balazs Sumegi , Kalman Takacs
IPC分类号： C07D295/12 , A61K31/155 , A61K31/16 , A61K31/40 , A61K31/4245 , A61K31/4453 , A61K31/454 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/5395 , A61K31/55 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/02 , A61P9/10 , A61P9/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/14 , A61P31/18 , A61P37/02 , A61P43/00 , C07C249/06 , C07C251/40 , C07D207/325 , C07D271/06 , C07D271/07 , C07D273/02 , C07D273/04 , C07D295/13 , C07D413/06 , A01N43/36 , A01N43/40 , A61K31/445 , A61K31/497
CPC分类号： C07D271/07 , C07C251/40 , C07D273/04 , C07D295/13 , C07D413/06
摘要： The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.
摘要翻译：本发明还涉及新的丙烯羧酸偕胺肟衍生物，另外还涉及N-氧化物和/或几何异构体和/或光学异构体和/或其药学上合适的酸加成盐和/或其季铵衍生物。新型化合物适用于治疗与缺氧和/或能量缺乏有关的状态，或者基于PARP抑制，特别是自身免疫性或神经变性疾病和/或病毒性疾病和/或由有毒的作用。

7. 发明授权

US06720337B2 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative 失效
标题翻译：具有增强的抗肿瘤活性和/或副作用降低的药物组合物，其含有抗肿瘤剂和羟基衍生物
公开(公告)号：US06720337B2
公开(公告)日：2004-04-13
申请号：US10106227
申请日：2002-03-27
申请人： Balazs Sumegi
发明人： Balazs Sumegi
IPC分类号： A61K31445
CPC分类号： A61K45/06
摘要： The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.
摘要翻译：本发明涉及具有增强的抗肿瘤活性或降低副作用的药物组合物，所述药物组合物包含具有抗肿瘤作用的已知活性物质或其药学上可接受的盐和式（I）的盐酸衍生物或治疗有用的酸加成盐其中。

8. 发明申请

US20070072912A1 Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants 审中-公开
标题翻译：脂环胺 - 胺取代的4-甲酰氨基 - 苯并咪唑作为对位抑制剂和抗氧化剂
公开(公告)号：US20070072912A1
公开(公告)日：2007-03-29
申请号：US10553937
申请日：2004-04-27
申请人： Kalman Hideg , Tamas Kalai , Balazs Sumegi
发明人： Kalman Hideg , Tamas Kalai , Balazs Sumegi
IPC分类号： A61K31/4439 , A61K31/4184 , C07D403/02
CPC分类号： C07D401/04 , C07D403/04 , C07D403/10 , C07D405/14 , C07D495/04
摘要： Compounds of the formula (I) and their pharmaceutically acceptable or technically applicable acid salts—where in the formula R1 represents hydrogen, C(1-4)alkyl or C(1-4)alkoxy R2 represents hydrogen, C(1-4)alkyl, carboxyl, C(1-4)alkoxycarbonyl, carboxamido, aryl or hetero-aryl R3 represents hydrogen, C(1-4)alkyl, aryl-methylene, or aryl, Y is a valency bond, a straight or branched chain C(1-4)alkene, a carbonyl-amino-C(1-4)alkene, or a —S—(CH2)m— group, where all alkene groups above may be spaced by an arylene group, n represents zero or the integer 1 m represents the integer 1, 2 or 3 Q represents hydrogen, hydroxyl or the oxygen radical (0) or together with the N atom of the adjacent ring forms a +N=O (oxoimmonium) group Z represents a single or double bond and their pharmaceutically acceptable or technically useful salts, processes for their preparation and their biological use as PARP inhibitors and antioxidants.
摘要翻译：式（I）化合物及其药学上可接受的或技术上可应用的酸盐 - 其中在式R 1表示氢，C 1-4（1-4） - 烷基或C （1-4）烷氧基R 2表示氢，C 1-4（1-4）烷基，羧基，C 1-4（1-4）烷氧基羰基，甲酰胺基，芳基或杂芳基R 3表示氢，C 1-4（1-4）烷基，芳基 - 亚甲基或芳基，Y是直链或支链C 1-4（1-4）烯烃，羰基 - 氨基-C 1-4（1-4） - 烯烃或-S-（CH 其中所有上述烯烃基团可以被亚芳基间隔开，n表示0或整数1m表示整数1,2或3个Q 表示氢，羟基或氧自由基（0）或与相邻环的N原子一起形成a + N = O（有机基元素）基团Z表示单键或双键及其药学上可接受或技术上有用的盐，准备 n及其生物用作PARP抑制剂和抗氧化剂。

9. 发明申请

US20070042935A1 Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect 有权
标题翻译：喹唑啉酮衍生物及其制备具有酶抑制作用的药物组合物的用途
公开(公告)号：US20070042935A1
公开(公告)日：2007-02-22
申请号：US10554749
申请日：2004-04-30
申请人： Balazs Sumegi , Kalman Hideg , Tamas Kalai
发明人： Balazs Sumegi , Kalman Hideg , Tamas Kalai
IPC分类号： A61K31/00
CPC分类号： C07D401/04 , C07D239/95 , C07D401/06 , C07D401/12
摘要： The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general formula (I) R1 stands for either hydrogen or a group of general formula (a); R2 stands for a) hydrogen or C1-6 alkyl group, if R1 is other than hydrogen, and b) if R1 is hydrogen, then R2 may be a group of general formula (b), (c) or (d). The subject of the present invention also embraces the preparation processes of the compounds described above.
摘要翻译：本发明的主题是抑制DNA修复酶，聚（ADP-核糖）聚合酶（PARP））的喹唑啉衍生物及其药学上可接受的通式（I）的盐，使其能够用于制备药物用于预防或治疗PARP抑制产生有益效果的疾病的组合物。在通式（I）中，R 1表示氢或通式（a）的基团; R 2代表a）氢或C 1-6烷基，如果R 1不是氢，和b）如果R' SUP> 1是氢，则R 2可以是通式（b），（c）或（d）的基团。本发明的主题还包括上述化合物的制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式